Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia.

Abstract

OBJECTIVE:

To compare the efficacy of two α1 -adrenoceptor antagonists, α1D -adrenoceptor-selective naftopidil (Naf) 75 mg and α1A -adrenoceptor-selective tamsulosin hydrochloride (Tam) 0.2 mg, for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).

METHODS:

Seventy-seven patients with LUTS secondary to BPH were enrolled. Data were gathered from patients retrospectively: 41 patients who were prescribed Naf 75 mg for 4 weeks and 36 patients who were prescribed Tam 0.2 mg for 4 weeks, respectively. The efficacy criteria were improvement in LUTS International Prostate Symptom Score (IPSS) and quality of life (QOL) scores after dosing.

RESULTS:

Naf 75 mg significantly improved symptoms in all 11 categories (overall IPSS, incomplete emptying, voiding symptoms [Intermittency, poor flow and straining], storage symptoms [daytime frequency, urgency and nocturia frequency], QOL index, intermittency, poor flow, straining, daytime frequency, urgency, and nocturia frequency) (P < 0.05). Tam 0.2 mg significantly suppressed 10 of the 11 tested symptom categories except straining (P < 0.05). Comparison data of the two drugs tended to show Naf 75 mg had better efficacy on nocturia frequency than Tam 0.2 mg (P < 0.05).

CONCLUSION:

Naf 75 mg might show a better efficacy for LUTS with BPH in nocturia frequency than Tam 0.2 mg.

• Authors: Katsumi Shigemura, Fukashi Yamamichi, Minori Matsumoto, Kazushi Tanaka, Masuo Yamashita, Soichi Arakawa, Masato Fujisawa
• Journal: Lower urinary tract symptoms (Low Urin Tract Symptoms) Vol. 4 Issue 3 Pg. 136-9 (Sep 2012) ISSN: 1757-5664 [Print] Australia
• PMID: 26676620 (Publication Type: Journal Article)
• Copyright: © 2012 Wiley Publishing Asia Pty Ltd.